

RECEIVED  
CENTRAL FAX CENTER

Tanox, Inc. DEC 27 2004



10301 Stella Link  
Houston, TX 77025  
(713) 578-4000  
FAX 713-578-5005

FAX TRANSMISSION COVER SHEET

**Date:** December 27, 2004  
**To:** Dr. Lorraine Spector  
**Company:** United States Patent & Trademark Office  
**Fax:** (703) 872-9306  
**Sender:** Cheryl A. Liljestrand  
**RE:** Response to Restriction Requirement

You should receive 3 page(s), including this cover.  
If you do not receive all pages, please call (713) 578-4182.

**Certificate of Transmission**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703)872-9306, on December 27, 2004

Typed or printed name of person signing this certificate:

Cheryl A. Liljestrand

Signature: Cheryl A. Liljestrand

**RECEIVED**  
**CENTRAL FAX CENTER**

DEC 27 2004

PATENT  
ATTORNEY DOCKET NO.: TNX98-03-01  
CUSTOMER NO: 26839

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:  
Ni, Baofu et al.

Serial No.: 10/071,962

Filed: February 8, 2002

For: G-CSF RECEPTOR AGONIST  
ANTIBODIES AND SCREENING  
METHODS THEREFOR

Group Art Unit: 1647

Examiner: L. Spector

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**

In response to the Restriction Requirement dated September 24, 2004, Applicants submit the following election. The period for response has been extended to December 24, 2004, by a Request for a two-month extension of time. Please charge our deposit account No. 20-0087.

Applicants elect Group I, Claims 31-45, drawn to agonist antibodies. Applicants further elect the species, Mab 163-93. The sequences corresponding to this antibody comprise SEQ ID NOs: 15-20 as indicated on page 27 of the specification.

Light chain sequences are as follows:

CDR-L1 – SEQ ID NO: 15; CDR-L2 – SEQ ID NO: 16; CDR-L3 – SEQ ID NO: 17;

Heavy chain sequences are as follows:


CDR-H1 – SEQ ID NO:18; CDR-H2 – SEQ ID NO:19; CDR-H3 – SEQ ID NO:20.

Applicants reserve the right to rejoin claims 46-47, upon a finding that the product claims are allowable.

Respectfully Submitted

Dated: December 27, 2004

BY:

  
Cheryl A. Liljestrand  
Reg. No. 45,275